Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $19.1 million.

  • Amicus Therapeutics' Accounts Payables rose 4170.31% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year increase of 4170.31%. This contributed to the annual value of $12.9 million for FY2024, which is 1437.17% down from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Accounts Payables is $19.1 million, which was up 4170.31% from $13.9 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Accounts Payables registered a high of $32.1 million during Q2 2024, and its lowest value of $9.2 million during Q1 2024.
  • For the 5-year period, Amicus Therapeutics' Accounts Payables averaged around $18.0 million, with its median value being $15.4 million (2022).
  • Over the last 5 years, Amicus Therapeutics' Accounts Payables had its largest YoY gain of 13707.29% in 2024, and its largest YoY loss of 6310.84% in 2024.
  • Amicus Therapeutics' Accounts Payables (Quarter) stood at $21.5 million in 2021, then dropped by 28.35% to $15.4 million in 2022, then dropped by 1.9% to $15.1 million in 2023, then dropped by 14.37% to $12.9 million in 2024, then skyrocketed by 47.55% to $19.1 million in 2025.
  • Its Accounts Payables was $19.1 million in Q3 2025, compared to $13.9 million in Q2 2025 and $14.5 million in Q1 2025.